Dear Colleagues,

Here is the Daily Briefing for 12 September 2017. Any feedback would be most welcome.

Best wishes,
Faraz Kermani, Communications Manager (External Affairs)

Specific Disease Areas

- **Desmoid tumor: All you need to know** *(12/09/2017) (Medical News Today)*
  Desmoid tumors are rare, noncancerous growths that develop in connective tissue, such as muscle.

- **Two studies show links between asthma and fertility treatment, and between e-cigarette vaping in mothers and asthma in offspring** *(12/09/2017) (Medical News Today)*
  Women with asthma are more likely to have fertility treatment before giving birth than non-asthmatic women.

- **Respiratory tract infections in young children linked to asthma and worse lung function in later life** *(12/09/2017) (Medical News Today)*
  An international study of 154,942 European children found that those who had had upper respiratory infections, such as colds, sinusitis, laryngitis, tonsillitis, pharyngitis and otitis, by the age of five years had a 1.5-fold increased risk of developing asthma in later life.

- **Cigarette smoke may ‘prime lung cells’ to develop cancer** *(11/09/2017) (Medical News Today)*
  New research has revealed how long-term exposure to cigarette smoke may alter lung cells in ways that make them sensitive to genetic triggers for cancer.

IP

- **New Study Looks At IP And The Rise Of Mega-Regional Agreements** *(11/09/2017) (Intellectual Property Watch)*
  A substantive new study with contributions from a range of leading thinkers in the field of intellectual property rights delves into the history and future of mega-regional trade agreements and the evolution of IP rights.
Policy

- **Patients to get easier access to medicinal cannabis under Greens bill**
  
  Australia's Greens leader confident bill will pass as he says Coalition ‘ignoring will of parliament’ on medicinal cannabis.

Human body/Lifestyle

- **Moving every 30 minutes may help you live longer**
  
  Researchers found that adults in the United States spend more than 12 hours per day sitting down, and the more time spent sitting, the greater their risk of premature death from all causes will be.

- **Study shows so-called 'healthy obesity' is harmful to cardiovascular heath**
  
  Academics at the University of Birmingham's Institute of Applied Health Research carried out the largest study of its kind to date comparing weight and metabolic status to cardiovascular disease risks.

Access

- **Trans-Pacific Partnership Agreement and Its Impact on Accessibility and Affordability of Medicines**
  
  A discussion of the main consequences of the implementation of the Trans-Pacific Partnership Agreement (TPPA) in the pharmaceutical sector in regard to public health, focusing on the accessibility and affordability of medicines.

Big Data / Real World Data

- **Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance**
  
  The arising Big data platform will help accelerate innovative discovery, development and delivery of new approaches in cancer care.

R&D

- **Pipeline Watch: Phase III Readouts For Gilenya, Duvelisib, Trimbow**
  
  Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

People

- **Teva poaches chief from Danish drugmaker Lundbeck**
  
  Teva has appointed Kare Schultz from Danish drugmaker Lundbeck to be its new chief executive, ending a seven month search which saw the Israeli pharmaceuticals company linked with AstraZeneca’s Pascal Soriot.
Companies

- **New Teva chief must tackle ‘tough decisions’ on jobs**
  (12/09/2017) (Financial Times)
  Teva’s newly appointed chief executive should not avoid “tough decisions” such as domestic job cuts as he seeks to revive the flagging Israeli drugmaker.

- **Teva Announces Sale of PARAGARD (intrauterine copper contraceptive) to CooperSurgical**
  (11/09/2017) (FirstWord Pharma)
  Teva today announced it has entered into a definitive agreement under which CooperSurgical will acquire Paragard (intrauterine copper contraceptive).

- **Vertex shuts down study of long-acting Kalydeco but insists development still on track**
  (11/09/2017) (STAT)
  Vertex Pharmaceuticals (VRTX) terminated a small clinical trial involving an important, long-acting version of its cystic fibrosis drug Kalydeco that was acquired from Concert Pharmaceuticals (CNCE) earlier this summer.

Pharmaceutical Industry

- **Healthcare in 2030: what role for pharma?**
  (11/09/2017) (Pharmaphorum)
  The healthcare systems of the future will be very different to those of today, with prevention and self-management increasingly important.

Regulatory

- **How the EU regulates medicines**
  (11/09/2017) (European Medicines Agency)
  The European Medicines Agency (EMA) will host an awareness session to present the European Union’s (EU) medicines regulatory system and EMA’s role in it to international regulators and NGOs.

Clinical Trials

- **Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology**
  (11/09/2017) (ScienceNewsline)
  Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at 3-5%.

- **Clinical trials registered prospectively are less likely to veer from protocols, study finds**
  (11/09/2017) (British Medical Journal)
  Journal editors, regulators, research ethics committees, funders, and sponsors should implement policies mandating prospective registration for all clinical trials.

International

- **Despite A Booming Economy, India’s Public Health System Is Still Failing Its Poor**
  (12/09/2017) (Forbes)
  Over the past decades, India’s rotting healthcare system has repeatedly disgraced its people.